Moderna Beheer

Beheer criteriumcontroles 2/4

De CEO Moderna is Stephane Bancel, benoemd in Oct2011, heeft een ambtstermijn van 11.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 18.16M, bestaande uit 5.5% salaris en 94.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.44% van de aandelen van het bedrijf, ter waarde CHF 2.68B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 8.8 jaar.

Belangrijke informatie

Stephane Bancel

Algemeen directeur

US$18.2m

Totale compensatie

Percentage CEO-salaris	5.5%
Dienstverband CEO	11.4yrs
Eigendom CEO	5.4%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	8.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Stephane Bancel's beloning veranderd ten opzichte van Moderna's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2022	n/a	n/a	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Compensatie versus markt: De totale vergoeding ($USD 18.16M ) Stephane } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.76M ).

Compensatie versus inkomsten: De beloning van Stephane is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Stephane Bancel (49 yo)

11.4yrs

Tenure

US$18,155,739

Compensatie

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% CHF 278.7m
Stephane Bancel	CEO & Director	11.4yrs	US$18.16m	5.44% CHF 2.7b
Stephen Hoge	President	no data	US$7.80m	0.46% CHF 227.6m
Shannon Klinger	Chief Legal Officer & Corporate Secretary	1.8yrs	US$11.76m	0.0015% CHF 743.3k
Juan Andres	President of Strategic Partnerships & Enterprise Expansion	5.6yrs	US$6.60m	0.0033% CHF 1.6m
James Mock	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Jerh Collins	Chief Technical Operations & Quality Officer	less than a year	geen gegevens	geen gegevens
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	6.4yrs	geen gegevens	geen gegevens
Brad Miller	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Lavina Talukdar	Senior VP & Head of Investor Relations	3.9yrs	geen gegevens	geen gegevens
Colleen Hussey	Senior Director of Corporate Communications	no data	geen gegevens	geen gegevens
Tracey Franklin	Chief Human Resources Officer	3.4yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0QF wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% CHF 278.7m
Stephane Bancel	CEO & Director	12yrs	US$18.16m	5.44% CHF 2.7b
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Elizabeth Tallett	Independent Director	2.7yrs	US$594.93k	0.00018% CHF 88.6k
Robert Langer	Independent Non Executive Director & Member of Scientific Advisory Board	12.3yrs	US$586.80k	2.98% CHF 1.5b
Scott Canute	Member of Technology Advisory Board	8.8yrs	geen gegevens	geen gegevens
Elizabeth Nabel	Independent Director	2yrs	US$633.39k	0.00018% CHF 88.6k
Fred Regnier	Member of Technology Advisory Board	8.8yrs	geen gegevens	geen gegevens
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jack Szostak	Chairman of Scientific Advisory Board	8.8yrs	geen gegevens	geen gegevens
John Aunins	Member of Technology Advisory Board	8.8yrs	geen gegevens	geen gegevens
Stephen Berenson	Independent Non Executive Director	5.4yrs	US$591.43k	0.0054% CHF 2.6m

8.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0QF wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).

Moderna Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna, Inc. Announces Board Changes

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Recent updates

Moderna, Inc. Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Moderna, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd